FDA Authorizes AI Model to Detect Heart Attacks in ECGs

What Happened

The U.S. Food and Drug Administration has authorized an artificial intelligence model called Queen of Hearts to detect heart attack patterns in electrocardiogram results. The algorithm is designed to identify STEMI and STEMI-equivalent patterns, a category of heart attack that requires rapid medical intervention and is among the leading causes of cardiac death globally.

Background

The Queen of Hearts model had previously received the FDA's Breakthrough Device Designation in 2025, a status the agency grants to technologies that show promise in diagnosing or treating life-threatening or irreversible conditions. That earlier designation accelerated the device's path through the regulatory review process. Full market authorization, announced in the most recent reporting period, represents the completion of that review and clears the technology for clinical use in the United States.

STEMI stands for ST-elevation myocardial infarction, a form of heart attack caused by a complete blockage of blood flow to part of the heart. STEMI-equivalent patterns are ECG findings that carry similar clinical urgency but do not display the classic ST-elevation signature. Identifying these patterns quickly is critical: treatment outcomes for STEMI patients are closely tied to the time elapsed between symptom onset and intervention.

ECG interpretation has historically depended on trained clinicians, and diagnostic accuracy can vary across settings, particularly in emergency departments with high patient volumes or facilities with limited specialist availability. AI-assisted interpretation tools have been developed to address variability in pattern recognition across these environments.

What the Technology Does

Queen of Hearts is built to analyze ECG data and flag STEMI and STEMI-equivalent patterns automatically. The algorithm processes the electrical signal data captured during a standard ECG and returns a classification intended to assist clinicians in making time-sensitive decisions about patient care.

The FDA's authorization covers this specific diagnostic function. The device is positioned as a clinical decision support tool, meaning it is intended to assist, not replace, physician judgment in interpreting ECG results.

Regulatory Context

The FDA's Breakthrough Device Designation program was established to accelerate the development and review of devices that address serious or life-threatening conditions. Designation does not guarantee approval but gives manufacturers more frequent contact with FDA staff during the review process and can reduce overall review timelines.

Authorization of AI-based diagnostic tools in cardiology has expanded in recent years. The FDA has cleared a growing number of algorithms for cardiac imaging and monitoring applications as manufacturers have sought regulatory approval for technologies trained on large clinical datasets.

A separate AI medical device story, involving Aidoc's First Read tool for drafting radiology reports, also received FDA Breakthrough Device Designation in the same reporting period. That product has not yet received full authorization.

What It Means in Practice

With FDA authorization in place, Queen of Hearts can be commercially deployed in U.S. clinical settings. Hospitals and health systems evaluating AI-assisted ECG interpretation tools can now consider the product for integration into their diagnostic workflows. The authorization applies to the specific indications covered in the regulatory submission: detection of STEMI and STEMI-equivalent patterns.

The scope of any initial deployments, including which hospital systems or health networks plan to adopt the technology, was not detailed in available reports at the time of publication.

What Comes Next

Commercial rollout of the Queen of Hearts model is expected to follow authorization, with adoption timelines to be determined by individual health system procurement and integration processes.